Stifel Financial Corp Has $195,000 Stock Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL)

Stifel Financial Corp lowered its holdings in shares of AbCellera Biologics Inc. (NASDAQ:ABCL) by 26.9% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 74,814 shares of the company’s stock after selling 27,563 shares during the period. Stifel Financial Corp’s holdings in AbCellera Biologics were worth $195,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of ABCL. Arcadia Investment Management Corp MI acquired a new position in AbCellera Biologics during the third quarter worth about $26,000. NBC Securities Inc. increased its position in AbCellera Biologics by 56.0% during the 3rd quarter. NBC Securities Inc. now owns 11,420 shares of the company’s stock worth $29,000 after purchasing an additional 4,100 shares in the last quarter. Evergreen Capital Management LLC bought a new position in AbCellera Biologics in the 2nd quarter valued at approximately $32,000. Ballentine Partners LLC acquired a new stake in AbCellera Biologics in the third quarter valued at approximately $54,000. Finally, Clarkston Capital Partners LLC acquired a new stake in AbCellera Biologics in the third quarter valued at approximately $57,000. 61.42% of the stock is currently owned by institutional investors.

AbCellera Biologics Price Performance

ABCL opened at $2.82 on Tuesday. AbCellera Biologics Inc. has a fifty-two week low of $2.34 and a fifty-two week high of $6.05. The company’s 50 day moving average price is $2.85 and its two-hundred day moving average price is $2.79. The firm has a market capitalization of $832.93 million, a price-to-earnings ratio of -4.62 and a beta of 0.41.

AbCellera Biologics (NASDAQ:ABCL) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The business had revenue of $6.51 million during the quarter, compared to the consensus estimate of $8.95 million. AbCellera Biologics had a negative return on equity of 15.73% and a negative net margin of 533.32%. During the same period in the prior year, the firm earned ($0.10) EPS. As a group, equities research analysts predict that AbCellera Biologics Inc. will post -0.59 EPS for the current year.

Analyst Ratings Changes

ABCL has been the subject of a number of research reports. Benchmark reiterated a “hold” rating on shares of AbCellera Biologics in a research note on Tuesday, November 5th. Stifel Nicolaus reiterated a “buy” rating and issued a $12.00 target price (down from $14.00) on shares of AbCellera Biologics in a research report on Tuesday, November 5th.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.